JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A1882 Cediranib (AZD217)

Target: VEGFR

Summary: VEGFR inhibitor receptor,highly potent

≥22.52 mg/mL
A2412 CP-724714

Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1R

Summary: HER2 inhibitor,potent and selective

≥23.5 mg/mL
A2251 Tivozanib (AV-951)

Target: VEGFR

Summary: VEGFR inhibitor,potent and selective

≥22.75 mg/mL
A1778 Vatalanib (PTK787) 2HCl

Target: VEGFR

Summary: Tyrosine kinase receptor inhibitor

≥21 mg/mL
A8370 Axitinib (AG 013736)
1 Citation

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR1/ c-Kit inhibitor

insoluble in H2O; ≥19.3 mg/mL
A8555 Vandetanib (ZD6474)

Target: VEGFR|EGFR

Summary: VEGFR2/EGFR antagonist

insoluble in H2O; ≥11.88 mg/mL
A3632 Motesanib

Target: VEGFR

Summary: Inhibitor of Flk-1/Flt-4/PDGFR-/c-Kit

≥42 mg/mL